Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Last Updated: Monday, November 21, 2022
This study examines the lack of access to CAR T-cell therapies for Black patients with multiple myeloma in the United States. This cross-sectional study uses data from 69 clinical trials across the United States, showing a limited opening of CAR T or bispecific antibody clinical trials in the states with the highest percentages of Black residents.
Advertisement
News & Literature Highlights
